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ColdG-protein coupled receptors (GPCRs) are generally considered to function as cell surface signaling structures
that respond to extracellular mediators, many of which do not readily access the cell's interior. Indeed, most
GPCRs are preferentially targeted to the plasma membrane. However, some receptors, including α2C-
Adrenoceptors, challenge conventional concepts of GPCR activity by being preferentially retained and
localized within intracellular organelles. This reviewwill address the issues associated with this unusual GPCR
localization and discuss whether it represents a novel sub-cellular niche for GPCR signaling, whether these
receptors are being stored for rapid deployment to the cell surface, or whether they represent immature or
incomplete receptor systems.logy, Johns Hopkins University,
ore, MD 21205, USA. Tel.: +1
l rights reserved.© 2011 Elsevier B.V. All rights reserved.To function correctly within a complex environment, cells must
detect signals in the extracellular space and initiate appropriate
intracellular responses to address the challenges imposed by the
stimulus. G-protein coupled receptors (GPCRs) represent the largest
family of proteins that enable cells to respond to signals that are
generally restricted to the extracellular milieu. They can mediate the
effects of ions, hormones, neurotransmitters, local autocoids, and
extracellular matrix components. GPCR activation is generally
mediated by binding of signals to the extracellular component of
the receptor, which cause conformational changes in the receptor
protein and lead to activation of heterotrimeric G-proteins located at
the inner surface of the plasma membrane. G-proteins then initiate
changes in cellular function by regulating the activity of intracellular
signaling mediators including enzymes, ion channels and transcrip-
tion complexes. Despite our standard view of GPCRs as cell surface
recognition sites, there is increasing evidence of a physiological role
for intracellular GPCRs. Although intracellular receptors can represent
a novel aspect of cell surface GPCR signaling following their
internalization, GPCRs can also be captured and retained within the
biosynthetic pathway before reaching the cell surface. The present
review will address the interesting dilemma resulting from this
preferential localization, focusing particular attention on the α2C-
adrenoceptor (α2C-ARs), and whether these intracellular receptorsrepresent a novel sub-cellular niche for GPCR signaling, whether these
receptors are being stored for rapid deployment to the cell surface, or
whether they represent immature or incomplete receptor systems.
1. Physiological role of α2C-Adrenoceptors
α2C-Adrenoceptors (α2C-ARs) belong to the α2 sub-family of
adrenoceptors that include α2A and α2B-subtypes. α2C-ARs are 462
amino acid long, class A GPCRs that are encoded by an independent
intronless gene located on human chromosome 4p16 [1–3]. The
physiological role of these receptors is tissue and cell-type dependent,
and has been primarily elucidated by animal models following genetic
ablation or overexpression, by identiﬁcation and characterization of
polymorphisms in the human population, and by examination of cells
expressing endogenous receptors. For example, the central and
sympathetic nervous system express α2C-ARs, which plays a key role
in pre-synaptic feedback inhibition (autoinhibition) of neurotransmit-
ter release. Prejunctional α2A-ARs regulate norepinephrine release
during high-frequency neuronal stimulation and likely represent a
mechanism for coordinating intense acute sympathetic responses. In
contrast, α2C-ARs modulate norepinephrine release at low frequency
stimulation andmay primarily regulate basal long term neurotransmit-
ter release [4,5]. The physiological signiﬁcance of α2-AR-mediated
autoinhibition was appreciated in mice with single or double knockout
of α2A- and α2C-AR subtypes, and by the discovery of a variant with
four amino acids deletion in the third intracellular loop of α2C-AR
subtype (α2C-Del322-325) in the human population, which impairs
effector coupling [5–7]. Mice deﬁcient in both α2A- and α2C-ARs
(double knockout) show elevated circulating plasma norepinephrine
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under non-stressful conditions. When challenged with chronic cardiac
left ventricular pressure overload and stress using transverse aortic
constriction, mice with deletion of α2A-ARs or α2C-ARs (single
knockouts) are also susceptible to increased incidence of hypertrophy
and ﬁbrosis, heart failure, and mortality compared with wild-type and
α2B-AR-deﬁcient mice [6]. Similarly, individuals with α2C-Del322-325
are at increased risk of developing heart disease [8,9], and heart failure
patients with this variant have adverse clinical status with decreased
cardiac function [6]. Studies in mice have also shown that central
nervous system α2C-ARs have a discrete role in behavioral responses
that include startle reﬂex, stress response, and locomotor activity [10],
while the α2A-AR subtype is responsible for sedation, analgesia, and
anesthetic-sparing effects [11,12].
Within the vasculature, α2-ARs are prominently expressed on
contractile vascular smooth muscle cells (VSM) in the blood vessel
wall [13]. The constrictor activity of α2-ARs is inversely related to the
size of the blood vessel and is most prominent in small vessels. For
example, VSM α2-ARs mediate constriction of arterioles (resistance
vessels) and veins, but not large arteries [14–16]. These arterioles
serve the unique role of “vascular faucets”, determining blood ﬂow to
organs and the cutaneous circulation and in generating peripheral
resistance [15]. α2-ARs, therefore, play an essential physiological role
in modulating blood vessel diameter and ﬂow. The remarkable
heterogeneity in α2-AR activity at different vascular sites is due to
differences in activation of α2-AR gene promoters [16]. Analysis of the
intact cardiovascular system in mice with genetic ablation of α2-AR
subtypes suggested that α2A- and α2B-ARs mediated vasoconstriction
to α2-AR stimulation, with α2A-ARs mediating the central antihyper-
tensive response [17–19].α2C-ARs were not considered to be involved
in vascular regulation, and were thought to be vestigial or silent
receptors [12,17,18]. Indeed, in small cutaneous arteries of the mouse
tail, α2-AR constriction at 37 °C is mediated by α2A-ARs, with no
apparent role for α2C-ARs [20]. However, moderate cooling (to 28 °C)
dramatically and rapidly increases the functional activity of α2C-ARs,
enabling these receptors to contribute to physiological cold-induced
augmentation of cutaneous vasoconstriction [20]. Cold-induced
cutaneous vasoconstriction plays a protective physiological role,
reducing loss of body heat and enabling maintenance of a normal
body core temperature [21]. In vivo studies have conﬁrmed the role of
α2C-ARs in cooling-triggered vasoconstriction in mouse and human
skin [22,23]. In human cutaneous arteriolar VSMs, endogenous α2C-
AR expression is markedly increased in response to serum stimulation
and by elevations in intracellular cyclic AMP levels, which can result
from increased expression of cyclooxygenase-2 [16]. α2C-AR expres-
sion was mediated by activation of the cyclic AMP-responsive EPAC
(exchange proteins activated by cyclic AMP) and the Ras-family
GTPase Rap1, which caused transcriptional activation of the α2C-AR
gene through JNK/c-Jun signaling [24,25]. Protein kinase A, the classic
cyclic AMP signaling pathway, did not have a physiological role in
α2C-AR expression. Together, these studies point to local action and
regulation of α2C-ARs in the microcirculation, and supported the
physiological role of α2C-ARs as “stress-receptors” of the vascular
sympathetic system [16,20,24,26].
2. α2C-Adrenoceptors as intracellular receptors
In contrast to α2A or α2B-ARs, α2C-ARs have a prominent
intracellular localization when expressed endogenously [27–29] or
in reconstituted cell systems [4,28,30–35]. By introducing a thrombin-
cleavable N-terminus into α2C-ARs, Daunt et al. demonstrated that
intracellular α2C-ARs were not cleaved by thrombin, suggesting that
they represented a resident and non-cycling pool of receptors (at least
in NRK cells) [31]. The magnitude of this intracellular pool of α2C-ARs
and the relative ability of these receptors to access the cell surface is
dependent on the cell type, with the largest proportion of cell surfacereceptors occurring in neuroendocrine cell lines (AtT20, PC12 cells),
although these cells still have a signiﬁcant intracellular component
[30,33]. It has generally been assumed that the mechanisms
responsible for intracellular retention of α2C-ARs are similar between
different cell types. However, available evidence suggests that it is not
the case and that α2C-ARs are characterized by a number of distinct
molecular species and distinct subcellular localizations, which is
determined by the cell type and experimental conditions.
α2C-ARs have generally been identiﬁed as three molecular species
with approximate molecular weights of 50–55 kD, 70–80 kD and 100–
120 kD [4,30,33,34,36]. The extracellular N-terminus of α2C-ARs is N-
glycosylated at two sites, and all three receptor species are glycoproteins.
The 50–55 kD species appear to represent a core glycosylated protein,
the 70–80 kD species a more extensively glycosylated receptor, and the
100–120 kD species comprising an SDS-resistant dimer of the 50–55 kD
protein [4,30,33,34]. After mutation of the N-glycosylation sites (N19
and N33) or treatment with peptide:N-glycosidase F (PNGaseF), which
cleavesN-linkedoligosaccharides, the 50–55 kDand70–80 kD forms are
reduced to a ~46 kD protein, and the 100–120 kD dimer reduced to
~90 kD species [30,33, authors unpublished observations]. Movement of
glycoproteins through the synthetic pathway can be assessed using
endoglycosidase H (EndoH), which distinguishes between immature,
high-mannose oligosaccharides (sensitive) and complex, mature moi-
eties (insensitive). Mannosidase II (MannII) completes the mannose
trimming reactions and gives rise to EndoH-resistant glycoproteins [37].
MannII is most often located in medial and trans-Golgi compartments,
although its exact location appears to be cell type speciﬁc [37,38]. The
50–55 kD and 100–120 kD species are EndoH-sensitive [30,33], which
suggests that they represent immature forms of the receptor and have
not accessed the distal components of the Golgi compartments. In
contrast, the 70–80 kD species is resistant to EndoH [30,33] suggesting
that these α2C-ARs have progressed to the medial and transGolgi
compartments. Indeed, when the cell-surface component of α2C-ARs
were selectively analyzed using cell membrane fractionation (HEK 293
cells), extracellular immunoprecipitation (HEK 293), or biotinylation
followed by photoafﬁnity labeling (MDCK II cells), theα2C-AR species on
the cell surface was found to be exclusively the 70–80 kD molecular
species [35,39]. Similarly, in cell types where α2C-ARs have a
predominant cell surface expression (AtT20, PC12) there is signiﬁcant
expression of this EndoH-resistant 70–80 kD species, whereas in cell
types that have a predominant or exclusive expression of intracellular
α2C-ARs (e.g. COS7 cells) expression appears to be restricted to the Endo
H-sensitive forms [33]. These results are consistent with the 70–80 kD
α2C-AR species representing amature formof the receptor and the other
species representing immature components that have not progressed to
the distal Golgi compartments.
Based on co-localization with organelle marker proteins or by
puriﬁcation of subcellular membranes, intracellular α2C-ARs have been
proposed to be localized and retainedwithin the endoplasmic reticulum
(ER), cis/medial Golgi and/or trans-Golgi compartments. In Rat1, NRK
and HEK293 cells, Hurt and colleagues observed that staining for α2C-
ARsoverlappedwithBiPor calreticulin (markers forER) andwithgiantin
or Mann II (used as markers of cis/medial Golgi), but lacked signiﬁcant
overlap with a trans-Golgi/endosome marker (mannose 6-phosphate
receptor, M6PR) [30,31,33]. In a more recent study in HEK 293 T cells,
Fillipeanu et al. observed that α2C-ARs in HEK 293 T cells were co-
localized almost exclusively with pDsRed2-ER, an ER marker, but only
“occasionally”withGM130, amarker for the cis-Golgi [32]. Despite slight
differences in localization, these investigators came to divergent
conclusions regarding the retentionofα2C-ARs. Fillipeanuet al. proposed
that intracellular retentionofα2C-ARs resulted froman intrinsic defect in
folding and export of the receptor from the ER [32]. The quality control
system of the ER is known to capture genetic mutations in certain
proteins (e.g. CFTR ΔF508, deletion of phenylalanine at residue 508),
which result in improper folding of the molecules [40–43]. Indeed,
prolonged treatment (18 h)ofHEK293T cellswith chemical chaperones
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42], increased the proportion of α2C-ARs able to bind the radioligand
RX821002 [32]. Misfoldedα2C-ARs in the ER do not effectively bind this
radioligand [33], so the observed increases in RX821002 binding would
be consistent with correction of a folding defect [32]. In contrast to this
proposal, Hurt and colleagues concluded that intracellular α2C-ARs are
notmisfolded but are retained in the ER by a distinctmechanism [30,33].
Indeed, they demonstrated using density-puriﬁed membrane prepara-
tions (or crude membrane preparations) that α2C-ARs within the ER
could bind RX821002 [30,33]. They subsequently identiﬁed a novel ER
luminal retentionmotif (ALAAALAAAAA) contained in the ‘extracellular’
amino-terminus of the α2C-ARs [30]. Deletion or mutation of this
retention motif was associated with increased maturation of α2C-ARs
and increased localization of the receptors on the cell surface.Wild-type
(wt) α2C-ARs were expressed almost exclusively as immature EndoH-
sensitive ~50 kD and ~100 kD species in HEK 293 cells [30]. However,
mutation or deletion of the putative ER luminal retention motif enabled
expression of a prominent EndoH-resistant ~70 kD α2C-ARs species,
which is consistent with progression of the immature species through
the distal compartments of the Golgi [30]. The divergent conclusions of
these studies are notmutually exclusive. Indeed, these studiesmay have
focused on distinct populations of ER-retainedα2C-ARs. Identiﬁcation of
a novel ER retention motif in correctly-folded α2C-ARs does not negate
the possibility that some α2C-ARs are also retained as misfolded
receptors and can be rescued by chemical chaperones. In contrast to
Hurt and colleagues [30,33], Fillipeanu et al. [32] focused on the
emergence of newRX821002 binding sites, which could have selectively
tracked the processing and maturation of misfolded α2C-ARs. However,
an increase in RX821002 binding sites (when employing crude
membrane preparations or intact cells [32,44,45]) need not be an
indication of cell surface receptors (see Section 3.2). Therefore, the
chaperone-induced appearance of new RX821002 binding sites ob-
served by Fillipeanu et al. [32] could still be retained in the ER (via the ER
luminal retentionmotif) or other intracellular location [33,46]. Hurt and
colleagues [30,33] focused on alternate approaches to study receptor
maturation and localization (e.g. immunoblot, immunoﬂuorescence),
which would be expected to identify misfolded and correctly-folded
α2C-ARs. Indeed, deletion or mutation of their novel ER retention motif
did not cause complete maturation of α2C-ARs, which could reﬂect the
continued presence of misfolded receptors [30]. Finally, Hurt and
colleagues [30,33] and Fillipeanu et al. [32] could potentially be studying
the same population of ER-retained α2C-ARs, with the ER luminal
retention signal maintaining the receptors in a non-functional confor-
mation with reduced ability to bind RX821002. This is considered
unlikely because removal of the ER retention motif (replaced with the
α2A-AR N-terminus) did not appear to increase the density of RX821002
binding sites [30].
The cytoplasmic C-terminus of the α2C-AR contains an RRRRR motif
(residues454 to 458),whichhas beendemonstrated to beapowerful ER
retention and retrieval mechanism. Indeed, when inserted into the C-
terminal of other plasma membrane proteins, this α2C-AR motif causes
them to be retained or retrieved to the ER and prevents their cell surface
expression [47,48]. Thismotif is an unusual form of the RXR family of ER
retention and retrieval system, which interacts with the coatamer
protein complex I (COPI) and mediate retrograde transport of proteins
from the proximal region of the Golgi back to the ER [42,47–49]. The
RRRRR motif is also present on the cytoplasmic tail of KA2 kainate
receptors, which causes the receptors to be retained in the ER in a COPI-
dependentmanner inCOS7orHEK293cells [49].Mutationof theRRRRR
motif decreased the association of KA2 with the COPI-subunits, β-COP
and α-COP, and caused a dramatic increase in the plasma membrane
levels of the protein [49]. Therefore, for α2C-ARs to escape the ER and
proximal Golgi compartments, this powerful retention signal must be
shielded or countered. For example, interaction with 14–3–3 protein
family members can prevent COPI binding to RXR motifs and enables
protein release from this ER retrieval pathway [49,50]. In Rat1 cells,where α2C-ARs have a prominent co-localization with the resident ER
protein calreticulin, removal of the RRRRR motif was reported not to
alter the intracellular localization of the receptor [30], although the
identity of the intracellular compartment for the mutant receptors was
not deﬁned. The presence of an additional ER luminal retentionmotif in
the extracellular region of α2C-ARs (as described above) [30] would
contribute to continued ER retention of α2C-ARs even in the absence of
the RRRRR motif. However, deletion or mutation of this ER luminal
retentionmotif enabled signiﬁcantmaturation and translocationofα2C-
ARs to the cell surface [30],which suggests that theRRRRRmotifwasnot
functioning as an ER retention or retrieval signal. It is not clear if this
reﬂects interaction of α2C-ARs with counteracting signaling mediators
(e.g. 14–3–3) or whether correctly-folded α2C-ARs (but perhaps not
misfolded receptors) normally mask the RRRRR motif [49,50].
In addition to retention of immature α2C-AR species in the ER and
proximal Golgi compartments,matureα2C-ARs have also been reported
to be retained in the trans-Golgi compartment. In HEK 293 cells, Jeyaraj
et al. observed co-localization of α2C-ARs in the trans-Golgi compart-
ment (ECFG-tagged peptide from the trans-Golgi enzyme β 1,4-
galactosyltransferase), and the sole expression of a mature EndoH-
resistant ~70 kD α2C-ARs species in density-puriﬁed Golgi membranes
[39]. In PC12 cells, which have a prominent cell surface population of
α2C-ARs [33] and a variable population of intracellular receptors [33,51],
there was considerable overlap between the intracellular pool of α2C-
ARs and mannose 6-phosphate receptor (M6PR), which is a marker for
trans-Golgi and endosomes [33]. Intracellular α2C-ARs in MDCK II cells
were also considered to be predominantly in the trans-Golgi compart-
ment [35], which was based on the partial co-localization of α2C-ARs
withMann II. As discussed above, this enzyme is most often localized to
the medial and trans-Golgi compartments, but its localization is cell
type speciﬁc and its co-localization with α2C-ARs has often been used
as evidence for cis/medial-Golgi localization. The exact localization of
α2C-AR within the Golgi therefore cannot be clearly deﬁned based on
Mann II. However, co-localization with Mann II is associated with a
higher expression of the mature 70–80 kD α2C-AR species and a higher
level of cell surface receptors compared to cell types where the
predominant α2C-AR localization is in the ER [31,33,35]. Therefore,
colocalization with Mann II indicates that α2C-ARs have accessed the
distal compartments of the Golgi and are fully mature receptors.
Although intracellular α2C-ARs appear to represent a stable pool of
resident receptors derived from de novo protein synthesis [31], there is
also evidence that cell surfaceα2C-ARsmay be internalized to the trans-
Golgi compartment. Indeed, the cell surface population of α2C-ARs in
NRK cells were internalized following stimulation with norepinephrine
and acquired a perinuclear localization that overlappedwith staining for
the trans-Golgi/endosomemarker M6PR [31]. The apparent trans-Golgi
staining for α2C-ARs in PC12 cells may reﬂect a naïve receptor
population or receptors that have been internalized from the cell
surface [33]. PC12 cells can synthesize norepinephrine. Although the
authors reported that an α2-AR antagonist did not affect plasma
membrane microdomains of α2C-AR, they did not report whether it
altered the perinuclear pool of α2C-ARs [33].
Despite the compelling evidence for the presence and retention of
α2C-ARs in distal Golgi compartments (including HEK 293 cells),
when characterizing a novel ER retention motif Angelotti and
colleagues concluded that the “Golgi apparatus would be less likely
for the site of action for the α2C-AR trafﬁcking signal in HEK 293 cells
because this compartment does not contain many quality control
enzymes or chaperones” [30]. Following deletion or mutation of the
ER luminal retention motif, approximately 50% of α2C-ARs remained
at intracellular sites although there appeared to be signiﬁcant
displacement from the ER marker protein calreticulin [30]. Therefore,
Angelotti et al. cannot discount the possibility that once freed from the
ER retention system, a signiﬁcant portion of α2C-ARs may be retained
within distal compartments of the Golgi. However, deletion or
mutation of the ER luminal retention motif may also have modiﬁed
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statement by Angelotti and colleagues, numerous proteins (including
GPCRs, see Section 3.1) are selectively targeted or retained within the
distal-Golgi compartments including the trans-Golgi [52–58].
Because of the presence of powerful retention systems for α2C-
ARs, overexpression of the receptor might be expected to saturate
retention systems and allowα2C-ARs to gain access to the cell surface.
Indeed, α2C-AR responses to extracellular agonists are observed in
most reconstituted cell systems even those with predominant
intracellular localization of the receptor, albeit at a lower level of
activity compared to other α2-AR subtypes. However, in NRK cells,
whereα2C-ARs have a predominant intracellular localization and only
faint plasma membrane staining, this pattern of localization was
observed regardless of the level of receptor expression [33]. This
suggests that α2C-ARs are not only actively captured by retention
systems within the cell, but that they are also actively exported to the
cell surface in a manner that bypasses or inhibits the retention signals.
The variation in subcellular distribution andmaturation ofα2C-ARs
between different cell types, and within the same cell type in different
studies (e.g. HEK 293 cells [30–32,39,59,60]) suggests that the
subcellular trafﬁcking and intracellular retention of α2C-ARs is
controlled by signaling pathways that promote or counter the
retention and export domains contained within the α2C-AR sequence.
Although some of these domains have been identiﬁed and character-
ized, other important regulatory domains and the signaling pathways
that control them await identiﬁcation. The variation in receptor
maturation and localization between different studies of the same cell
type likely reﬂect alterations in experimental approach (e.g. serum-
containing [39] versus serum-free conditions [32]) that may dramat-
ically impact these regulatory signaling pathways.
3. The Functional signiﬁcance of intracellular GPCRs and
α2C-Adrenoceptors
3.1. Storage depots
Mature GPCRs can be stored in distal Golgi compartments,
including the trans-Golgi, and following the appropriate cell stimu-
lation they can be translocated rapidly to the cell surface. For example,
the ability of cells to maintain sensitivity to thrombin is mediated in
part by translocation of naïve receptors from a stable pool retained in
the trans-Golgi compartment [61]. Thrombin (and other protease-
activated) GPCRs are activated by a unique mechanism, whereby
thrombin cleaves the receptor's amino-terminal exodomain to
uncover a tethered peptide ligand [61]. This irreversible proteolytic
activation renders the receptor unresponsive to subsequent throm-
bin-induced activation [61]. Indeed, following stimulation, the re-
ceptors are rapidly internalized and targeted to lysosomes for
degradation and are not recycled to the cell surface as occurs with
other GPCRs (e.g. β2-ARs) [61]. In transfected Rat1 ﬁbroblasts,
thrombin receptors localized to the plasma membrane and to a
perinuclear distribution, which colocalized with Mann II and the
ﬂuorescent ceramide analog C6-NBD-ceramide, markers for the trans-
Golgi compartment [62,63]. Thrombin stimulation caused internali-
zation and subsequent degradation of cell surface receptors, which
was paralleled bymobilization of these naïve intracellular receptors to
the cell surface with almost complete recovery of the cell surface
receptor pool and responsiveness to thrombin, together with loss of
intracellular receptor storage, all within 1 h [61]. Mobilization of
receptors from intracellular pools within the Golgi compartment can
also contribute to maintained sensitivity or reduced desensitization of
non-protease GPCRs. In HEK 293 cells, M2 receptors were localized to
the cell surface and a prominent perinuclear compartment that
colocalized with medial/trans-Golgi markers (Mann II, α2,6-sialyl-
transferase) [64]. The muscarinic agonist carbachol caused a rapid
mobilization of this intracellular receptor pool, increasing the densityof cell surface receptors while depleting the intracellular compart-
ment [64]. This mobilization of receptors partially masked the
agonist-induced internalization of M2Rs associated with receptor
desensitization [64]. Activation of cell surface GPCRs can also cause
mobilization of distinct cell surface receptors from the trans-Golgi
compartment. In human umbilical vein endothelial cells (HUVECs),
the non-GPCR vascular growth factor receptor-2 (VEGFR2) is localized
to the plasma membrane whereas the non-GPCR VEGFR1 has a
predominant stable perinuclear localization and co-localizes with the
trans-Golgi markers TGN46 and GalT, and also with cis/medial Golgi
markers (GM130, Mann II)[65]. Indeed, there appeared to be two
distinct pools of VEGFR1: one in the trans-Golgi and one in cis-Golgi,
with serum starvation or inhibition of protein synthesis depleting the
cis-Golgi pool and increasing the trans-Golgi pool [65]. Activation of
HUVECs by VEGF-A, histamine or thrombin caused a rapid mobiliza-
tion of VEGFR1 from the trans-Golgi to the plasma membrane,
attaining a 2-fold increase within 15 min [65]. VEGFR1mobilization to
the cell surface was mediated by elevation in cytoplasmic calcium,
was inhibited by the calcium ion chelator BAPTA-AM and stimulated
by calcium ionophore (A23187) or thapsigargin, which causes
calcium release from intracellular stores [65]. Elevation in cytoplasmic
calcium may also contribute to the depolarization-induced translo-
cation of δ opiod receptors (DORs) from intracellular membranes to
the cell surface of cerebral and spinal cord neurons [66]. When
expressed in PC12 cells, DOR was expressed predominantly at the
plasma membrane, which is also where they localize in non-neuronal
cells [66]. However, exposure of the cells to nerve growth factor
(NGF), which stimulates differentiation of PC12 cells, or to epidermal
growth factor (EGF) caused the generation of an intracellular pool of
DOR [66]. This was not the result of receptor internalization, and
indeed NGF did not stimulate DOR internalization. Rather NGF caused
selective intracellular targeting of recently synthesized, mature
EndoH-resistant DORs from the biosynthetic pathway [66]. As with
VEGFR1 receptors, there was pronounced overlap between DOR
staining and that of TGN38 a trans-Golgi marker and with GM130,
which is associated with cis-Golgi membranes. Chase experiments
conﬁrmed that this intracellular pool is not simply a reﬂection of
increased DOR synthesis and represents a stable pool of intracellular
receptors. An undeﬁned Golgi-retention motif was localized to the C
terminal of DOR. The intracellular pool of DORs could be rapidly
mobilized in response to depolarization with KCl (30 min), which
caused decreased amounts of DOR at intracellular sites and increased
density at the plasma membrane consistent with translocation of the
receptor [66]. Thus, mature intracellular receptors can be rapidly
mobilized from the distal compartments of the Golgi compartments
to maintain responsiveness or modify the signaling responses to
receptor agonists or to uncover responses to independent agonists. In
an analogous fashion to receptor desensitization [67], sensitization or
resensitization of receptors may therefore occur in a homologous
(agonist or receptor-speciﬁc) or heterologous (receptor-independent)
manner.
In the vascular system, α2-AR activity is dramatically increased in
cutaneous blood vessels, where these receptors play an important role
in thermoregulation [14,68–70]. During local or whole body cooling,
blood ﬂow to the skin is reduced to prevent heat loss, which is
mediated by a reﬂex increase in sympathetic tone and by a direct
effect of cold on the cutaneous blood vessels [21]. This latter effect
dramatically and selectively sensitizes the vessels to vasoconstriction
mediated by the sympathetic neurotransmitter, norepinephrine, and
is mediated by a rapid and selective, cold-induced increase in α2-AR
function [14,68,71–74]. Indeed, in individuals with Raynaud's phe-
nomenon, which is characterized by enhanced sensitivity to the direct
effect of cold, α2-AR antagonism prevents cold-induced vasospastic
attacks [75,76]. Cold-induced ampliﬁcation of α2-AR activity in
cutaneous arteries was subsequently demonstrated to be mediated
by a selective effect of cooling to amplify or uncover responses to α2C-
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α2-AR stimulation in mouse isolated tail arteries was mediated by
α2A-ARs with no apparent contribution from α2C-ARs [20]. However,
during cold exposure (28 °C, 30 min), the augmented α2-AR response
was mediated by α2C-ARs and was abolished by inhibition of α2C-ARs
[20]. In HEK293 cells transfected with α2-ARs, α2A-ARs were
expressed on the cell surface and responded to activation by
regulating adenylyl cyclase activity [39]. Cooling (to 28 °C) did not
inﬂuence α2A-AR location or function. In contrast, α2C-ARs were not
functional at 37 °C and were localized, by sub-cellular fractionation or
immunoﬂuorescent techniques, to the trans-Golgi compartment [39].
Cooling (to 28 °C) caused redistribution of α2C-ARs to the cell surface
and rescued the α2C-AR functional response, demonstrated by
agonist-dependent regulation of adenylyl cyclase [39]. Subcellular
fractionation revealed that the α2C-AR leaving the Golgi and
translocating to the plasma membrane in response to cold was the
mature Endo-H resistant ~70 kD species [39]. This translocation was
relatively rapid, enabling a 3 to 4-fold increase in cell surface α2C-ARs
within 1 h, and occurred in the absence of new protein synthesis or
changes in the total expression of the receptor [39,59,60]. The
thermosensor responsible for initiating this effect appears to the
mitochondria. On exposure of vascular and other cells to lower
temperatures, there was an immediate increase in the generation of
reactive oxygen species (ROS) from the mitochondria [59]. Mito-
chondria-derived ROS activated RhoA and Rho kinase (ROCK), and
this signaling pathwaywas responsible for cold-induced ampliﬁcation
of α2-AR constriction, for uncovering functional responses to α2C-AR
stimulation and for enabling the rapid cold-induced translocation of
α2C-ARs to the cell surface [59,60]. Therefore, although originally
considered as thermosensors [20,68], α2C-ARs do not respond directly
to changes in temperature and are actually thermo-effectors,
responding to a cold-induced signal transduction pathway. Therefore,
these results indicate that cold-induced vasoconstriction in cutaneous
arteries results from a rapid cold-induced functional rescue of silent
α2C-ARs, mediated by a cold-induced increase in mitochondrial ROS
and activation of RhoA and ROCK. In a reconstituted cell system
(HEK293 cells), cold exposure also caused a rapid functional rescue of
α2C-ARs, which was paralleled by a ROS and ROCK-dependent rapid
translocation of matureα2C-ARs from the trans-Golgi compartment to
the cell surface. The mechanisms underlying the ability of RhoA and
ROCK to stimulate translocation of α2C-ARs from the trans-Golgi to
the cell surface of HEK 293 cells has not been deﬁned [60]. It may reﬂect
actions of ROCK on α2C-ARs, the biosynthetic pathway including
chaperones or cargo proteins, and/or changes in plasma membrane
microdomains that increase the ability of α2C-ARs to be inserted or
remain at the cell surface. Translocation of other GPCRs from the trans-
Golgi to the cell surface occurs in response to elevations in intracellular
calcium [65,66]. Indeed, calcium and ROCK may be acting through a
common signaling pathway, e.g. to regulate myosin-light chain phos-
phorylation and the cytoskeleton.
Because signaling through ROS/RhoA/ROCK can stimulate α2C-ARs
translocation to the cell surface and uncover α2C-AR functional
responses [60], α2C-AR activity may be increased by heterologous
sensitization, i.e. in response to activation by other vasoconstrictor
stimuli. Vasoconstriction to α2-AR activation is a relatively weak
response and is generally rather difﬁcult to observe and analyze
[20,77–79]. Indeed, to assess vascularα2-ARactivity,many investigators
ﬁrst activate arteries with an independent constrictor agent (e.g.
angiotensin II or serotonin) to help uncover or amplify the α2-AR
response [80–82]. The mechanisms (including the α2-AR subtype)
underlying this “rescue” ofα2-AR function has not been clearly deﬁned,
butmay reﬂectmobilization ofα2C-ARs, e.g. through activation of RhoA/
ROCK. Indeed, in the rat tail artery, which has only a weak α2-AR
constrictor response [73,82], responses to α2-AR activation were
mediated by α2C-ARs in the presence of a pre-constricting agent
(serotonin) [83] but not when studied under basal conditions [84].3.2. Stunted development
Proteins can be captured or retained within the early stages of the
biosynthetic pathway as a result of inherent defects in protein folding
and maturation, which commonly occur as a result of genetic
mutations [e.g. cystic ﬁbrosis transmembrane conductance regulator
(CFTR), the ATP-binding cassette subfamily B member 4 (ABCA4), and
vasopressin type 2 receptors (V2Rs)], resulting in chaperone-linked
retention of these proteins by the quality control mechanisms of the
ER [41,42,85,86]. Chaperone-linked capture and retention of normal
proteins can also optimize association with key signaling partners,
including oligomerization of GPCRs [87–89]. There is evidence that
these mechanisms can contribute to the retention of α2C-ARs within
the ER.
From the perspective of α2C-ARs and their role in thermoregula-
tion, it is especially intriguing that prolonged exposure of cells to low
temperatures counters the ER retention of misfolded mutant proteins
including genetic mutations in CFTR, ABCA4 and V2Rs [41,42,85,86]. A
genetic deletion of phenylalanine at residue 508 (ΔF508) of the CFTR
results in a folding defect in the protein that largely prevents the
protein from exiting the ER where it is retained as an immature
EndoH-sensitive glycoprotein [41,85]. At low temperatures (27 to
32 °C), ΔF508 CFTR exits the ER, acquires Golgi-speciﬁc N-linked
glycanmodiﬁcations rendering it EndoH-resistant, and translocates to
the cell surfacewhere it can function as an ion channel [41,85] This is a
slow process, being evident only after 12 h and maximal after 72 h
[85]. Cold exposure alters the interaction of the mutant CFTR protein
with ER chaperones and export proteins: it reduced the interaction
between ΔF508 CFTR and HSP90, but increased the association of the
CFTR mutant with HSP70 and subsequently with the COPII ER cargo
selection subunit Sec24 [41]. The COPII system is responsible for
generating transport vesicles for delivery of cargo to the Golgi [90].
Directly disrupting the interaction between ΔF508 CFTR mutant and
HSP90 (or co-chaperones) at warm temperatures was also associated
with functional and spatial rescue of the mutant protein [90,91].
Exogenous chemical chaperones (e.g. DMSO) can also stabilize the
protein fold of mutant proteins, and they promoted ΔF508 CFTR
export at physiological temperatures, albeit after prolonged incuba-
tion (up to 2 days) [40,41]. Therefore, ΔF508 CFTR appears to be
trapped in a chaperone-linked folding intermediate within the ER,
which can be countered by prolonged exposure to low temperatures.
Interestingly, this cold-induced rescue of ΔF508 CFTR and V2R is cell-
type speciﬁc indicating that appropriate signaling/chaperone systems
need to be in place [41,42].
The cold-induced, slow functional and spatial rescue of misfolded
immature mutant proteins from the ER is clearly very different from
the reported rapid cold-induced translocation ofmatureα2C-ARs from
the trans-Golgi to the cell surface. However, Filipeanu and colleagues
recently concluded that the intracellular retention of α2C-ARs in HEK
293 T cells resulted from an intrinsic defect in folding and export of
the native receptor from the ER [32]. Furthermore, they proposed that
exposure to low temperatures facilitates receptor stabilization and
allows its inclusion in the export trafﬁcking pathway [32]. Exposure of
HEK 293 T cells to cool temperatures (30 °C) caused a slow increase in
the density of α2C-ARs that bound the α2-AR ligand RX821002, which
attained statistical signiﬁcance after 6 h and peaked after 18 h [32].
Similarly, prolonged treatment (18 h) with chemical chaperones
(DMSO, glycerol) or HSP90 inhibitors also increased RX821002
binding density at 37 °C but had no effect at 30 °C [32]. As with the
ΔF508 CFTR mutant protein, co-immunoprecipitation experiments
demonstrated interaction between HSP90 and α2C-ARs at 37 °C,
which was dramatically reduced following prolonged exposure to
30 °C (18 h) [32]. These effects are consistent with observations on
misfolded mutant proteins, but are in marked contrast to previous
reports demonstrating a rapid cold-induced translocation of mature
α2C-ARs from the trans-Golgi to the cell surface [39,59,60]. In contrast
1500 M.A. Chotani, N.A. Flavahan / Biochimica et Biophysica Acta 1813 (2011) 1495–1503to those previous studies, which relied on antibody-based techniques
to assess α2C-AR localization [39,59,60], Filipeanu and colleagues
employed radioligand binding of RX821002 to crude cell membrane
preparations or intact cells in an attempt to quantify cell surface α2C-
ARs [32,44]. Crude cell membrane preparations contain receptors
from plasma membranes and intracellular organelles and cannot be
used to quantify cell surface receptors. Indeed, RX821002 can bind
intracellular α2C-ARs in NRK cells when present within crude
membrane preparations or density-puriﬁed intracellular membranes
[33]. Likewise, when used in intact cells, RX821002 can bind to cell
surface and intracellular α2C-ARs [46]. Incorrectly processed, mis-
folded α2C-ARs cannot effectively bind RX821002 [30]. Therefore,
focusing on increased RX821002 binding sites would be expected to
emphasize the emergence of functional receptor molecules from the
synthetic pathway, rather than track translocation of receptors to the
cell surface. To quantify total receptor density (i.e. cell surface plus
intracellular sites), Filipeanu et al. elected not to utilize RX821002
binding (presumably because it matched the magnitude of their ‘cell
surface’ receptors) but instead quantiﬁed total receptor density using
GFP-tagged receptors, which would comprise both functional and
non-functional receptors. The results of Filipeanu et al. are consistent
with a component of intracellular receptors being retained as a
chaperone-linked misfolded protein in the ER that can be corrected by
prolonged exposure to low temperatures and enable a slow increase in
binding sites for RX821002 [32]. However, rapid cold-induced mobiliza-
tion of matureα2C-ARs from the trans-Golgi to the plasmamembrane, as
previously reported [39,59,60],wouldnot be expected to alter the density
of functional RX821002 binding sites. Because they aremature receptors,
they should bind RX821002 when present on trans-Golgi or plasma
membranes, andwould have been detected using RX821002 in crude cell
membrane preparations or intact cells [30,33,46]. Filipeanu et al. also
demonstrated that prolonged exposure to cold (18 h, 30 °C) increased
the density of RX821002 binding sites in density-puriﬁed plasma
membranes and caused marked relocation of GFP-tagged α2C-ARs to
the plasma membrane [32]. This analysis was performed only after
prolonged exposure to cold (18 h) and therefore cannot discount a rapid
translocation of mature α2C-ARs followed by a slower emergence of
previously-misfolded receptors from the ER. Concomitant with the rapid
cold-induced translocation of mature α2C-ARs to the cell surface, Jeyaraj
et al. demonstrated a rapid emergence of a functional response toα2C-AR
stimulation (inhibition of cyclic AMP accumulation) [39]. In contrast,
Filipeanu et al. were unable to observe a functional response until after 6
to 18 h of cooling [32]. This suggests that either the expression ofα2C-ARs
was insufﬁcient to elicit a functional response until misfolded receptors
had been released from the ER, or there are clear differences between
these studies in the manner in which HEK 293 cells process α2C-ARs.
Indeed, in the study by Filipeanu et al., the predominant α2C-ARs appear
to be the immature ~50 kD species, which would be consistent with
retention in the ER. Interestingly, the molecular size of this receptor did
not change on exposure to prolonged cooling [32], whichmight suggest a
lack of receptor maturation. Clearly, the marked differences in behavior
and characteristics of the α2C-ARs in different studies of HEK 293 cells
suggest that changes in experimental approach and handling of these
cellsmay alter the activity of chaperones in the biosynthetic pathway and
the subcellular retention and localization of these receptors.
Filipeanu et al. also proposed that the rapid cold-induced ampliﬁ-
cation of α2C-AR vasoconstriction in cutaneous arteries is mediated by
correction of an inherent defect in receptor folding and ER retention
[32]. The authors observed that short-term exposure to cold (1 h) or to
HSP90 inhibition (30 min) ampliﬁed contraction of rat tail arteries to
the selective α2-AR agonist UK 14,304 [32]. The time course of these
rapid vasomotor changes is obviously not consistent with slow cold-
induced export of misfolded proteins, including α2C-ARs, from the ER
[32,85]. The authors did not conﬁrm that the effects of the HSP90
inhibitorweremediated byα2C-ARs nor did they rule out the possibility
of non-speciﬁc changes in vascular reactivity. Indeed, the effects of theinhibitorweremostmarked athigh concentrationsofUK14,304 that are
known to activate α1-ARs [83,92]. Rapid cold-induced ampliﬁcation of
α2C-AR activity in the cutaneous circulation is more consistent with
translocation of mature receptors from the trans-Golgi rather than the
slowemergenceof correctly-folded receptors from theER.However, the
mechanism identiﬁed by Fillipeanu et al. whereby prolonged exposure
to low temperatures counters ER-retention of α2C-ARs and causes a
post-translational increase in α2C-AR binding sites might contribute to
more chronic changes in thermosensitivity and cutaneous blood ﬂow.
As occuring with other GPCRs [87–89], α2C-ARs can attain cell
surface expression through oligomerization with distinct receptors.
Prinster et al. analyzed 25 distinct GPCRs, but found that only β2-ARs
could facilitate cell surface localization and functional rescue of α2C-
ARs in HEK 293 cells detected using a cell surface ELISA [34]. This was
associated with an increase in density of binding sites for the α2-AR
ligand, rauwolscine (using crude membrane preparations), which the
authors considered likely reﬂected the reduced retention of immature
α2C-ARs in the ER [34]. It is not known if interactionwith β2-ARs alters
the putative HSP90-mediated retention of α2C-ARs in the ER. α2C-ARs
can also dimerize with α2A-ARs, but this does not alter the cellular
localization of the receptor [4] (see also Section 3.3).
3.3. Signaling domains
Early research highlighted the signaling events involved in desen-
sitization and internalization of GPCRs, including phosphorylation of
agonist-occupied receptors by G-protein-coupled receptor kinases
(GRKs), recruitment of β-arrestin and subsequent capture and
endocytosis of GPCRs by clathrin-coated pits [67,93,94]. Internalization
of receptors was thought to merely be a key component of desensiti-
zation, with the receptors being delivered to lysosomes for degradation
or being rapidly recycledwithin the endosomal system (separated from
ligands, dephosphorylated) and returned to the plasma membrane.
More recent research indicates that internalization of GPCRs bestows
novel signaling characteristics on these receptors. The possibility for
endosomal signaling was elegantly demonstrated in studies of receptor
tyrosine kinases [94]. For example, internalization of activated NGF
receptors (TrkA) and transport of receptor-containing endosomes
within neurons is required for TrkA to initiate effective nuclear signaling
[94,95]. Regarding GPCRs, in addition to facilitating receptor internal-
ization, β-arrestin functions as a scaffolding protein to recruit com-
ponents of the MAPK signaling pathway and facilitate ERK activation
[94]. Internalized endosomal GPCRs are thought to be capable of
maintained signaling through ERK, Akt, and adenylyl cyclase and to
initiate cellular responses distinct from cell surface receptors [94,96,97].
The concept that internalized receptors are recycled directly back to the
cell surface has also been challenged by the observation that
internalized GPCRs can be directed to and retained within the trans-
Golgi compartment, colocalizing with TGN38 [98,99]. Therefore, a
mobilizeable pool of cell-surface receptors in distal Golgi compartments
(Section 3.1) could be generated by retention of newly-synthesized
receptors but also fromcapture of receptors cycling fromthecell surface.
Although α2C-ARs are expressed predominantly as an intracellular
receptor, when present on the cell surface they are resistant to
phosphorylation by GRKs resulting in reduced interactionwith β-arrestin
and decreased desensitization and internalization compared to other α2-
ARs [4,36,100–102]. It is not clear whether mobilization of α2C-AR from
intracellular stores in response to agonist stimulation (i.e. homologous
sensitization) might also contribute to reduced sensitivity of α2C-ARs to
desensitization. Although oligomerization betweenα2A-ARs andα2C-ARs
does not change the cellular localization of these receptors, the interaction
alters the signaling characteristics of α2A-AR and its interaction with β-
arrestin [4]. As expected, basedon sensitivity of the individual receptors to
GRKs, norepinephrine treatment caused recruitment of β-arrestin-GFP to
plasma membranes of cells expressing α2A-ARs but not in separate cells
expressing α2C-ARs. Intriguingly, when α2C-ARs were co-expressed with
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recruitment of β-arrestin was reduced [4]. Furthermore, although co-
expressionofα2C-ARswithα2A-ARsdidnot alternorepinephrine-induced
ERKactivation, it reducednorepinephrine-induced activation ofAktwhen
compared to theα2A-AR alone. Therefore, despite a limited access ofα2C-
ARs to the cell surface, the presence of these receptors can dramatically
reduce α2A-AR desensitization and alter α2A-AR activity. It is not clear
whether these events are inter-related and whether theα2A-AR relies on
internalization and endosomal signaling for this Akt signaling response.
BRET analysis demonstrated that α2C-ARs and α2A-ARs can also form
homodimers although heterodimerization appears to be the favored
process [4]. There was no identiﬁcation of the α2C-AR molecular species
interacting with α2A-ARs [4] or whether oligomerization was associated
with increased maturation of the α2C-ARs species. Certainly, α2C-ARs
homodimers appeared to focus on~50and~100 kDspecies,whichwould
be consistent with lack of maturation of these receptors [4].
Aswith internalizingendosomal receptors, functional GPCRs that are
retained within the secretory pathway appear fully capable of initiating
signaling responses following activation by appropriate agonists.
Indeed, heterotrimeric G-proteins are assembled and incorporated
into membranes in the ER and can be found on membranes of the ER,
Golgi compartments, and endosomes [94]. Furthermore, GPCRs can
associate with heterotrimeric G-proteins and effector enzymes within
the ER [103,104]. Perhaps the most remarkable demonstration of
signaling by receptors retained within the biosynthetic pathway is with
mutant vasopressin 2 receptors (V2Rs) that are responsible for
Nephrogenic Diabetes Insipidus (NDI). Most of NDI mutations result
in inherently functional receptors that are however misfolded and as a
result retainedwithin the ER. Therapeutic strategies have been directedFig. 1. Regulation of intracellular GPCR (including α2C-ARs) activity. Newly synthesized GPC
control and retention/retrieval mechanisms (designated as red 5th and 6th transmembr
pharmacological) can counteract quality control and chaperone-mediated retention of GP
Receptor maturation is associated with alterations in the glycosylation of the proteins, and
GPCRs can be retained in the trans-Golgi compartment for rapid transport to the cell surface
same GPCR (homologous) or distinct GPCRs (heterologous sensitization). Intracellular rec
accessing the intracellular compartments (GPCR activation designated by starbursts). Cell
phosphorylation (by GRKs, designated by red 3rd intracellular loop) and internalization viaat using chemical or pharmacological chaperones to rescue the mutant
V2Rs [42]. However, a recent study demonstrated that functional but
misfolded mutant V2Rs that are retained in the ER can be activated by
non-peptideagonists (but not vasopressin)at their intracellular location
and can initiate normal cellular responses, including elevations in cyclic
AMPandmodulation of Aquaporin-2 activity [43]. The receptor agonists
did not alter the intracellular localization of the mutant receptors and
did not promotematuration of the receptor species. Indeed, as a result of
their intracellular localization, the intracellular receptors were not
subject to the normal desensitization and degradation occurring with
wild-typeV2Rs [43]. It is not yet clear if this phenomenoncanoccurwith
intracellularα2C-ARs, either byphysiological or pharmacologicalmeans.
The classical physiological agonists for α2C-ARs, norepinephrine or
epinephrine, are normally restricted to the extracellular environment.
However, these agonists can gain access to the intracellular environ-
ment during catecholamine biosynthesis and during neuronal or
extraneuronal uptake. Depending on the spatial relationship between
intracellularα2C-ARs, catecholamineuptake/biosynthetic pathways and
catecholamine degradative enzymes, this might provide an additional
mechanism for α2C-AR activation and regulation of cellular responses.
α2-ARsmay alsobeactivated bynon-traditional pathways. For example,
α2-ARs can be stimulated by L-arginine and its metabolites [105]
providing an alternate route for activation of intracellular α2C-ARs.
Intracellular GPCRs including α2C-ARs provide cells with the ability
to rapidly alter the nature or magnitude of cellular response to agonist
stimulation (Fig. 1). These receptors should not be characterized solely
in terms of storage depots, stunted development or signaling domains.
Rather, they can function simultaneously within all three categories
(Fig. 1).Rs can be retained in the ER as a result of misfolding and/or chaperone-linked quality
ane domains). Prolonged cooling, cell signaling or exogenous chaperones (chemical,
CRs in the ER, enabling transport of the receptors through the Golgi compartments.
acquisition of EndoH-resistance (designated as changes in GPCR N-terminus). Mature
in response to cell signaling activated by acute cooling, and by agonists stimulating the
eptors retained in the biosynthetic pathway can be activated by agonists capable of
surface receptors can also be translocated to the trans-Golgi compartment following
the endosomal pathway.
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